| abstract |
Human monoclonal antibodies that specifically bind to M-CSF, and methods for their production are disclosed. The antibodies may be used in the treatment of M-CSF mediated diseases, such as rheumatoid arthritis and cancer. An alternative embodiment relates to humanized and chimeric antibodies against M-CSF. Isolated heavy and light chains derived from the human anti-M-CSF antibodies are also provided. |